Notably, GHK-Cu levels in circulation are known to decline with age, a pattern that has fueled substantial research interest in the peptide's potential relevance to tissue aging and regenerative capacity over the lifespan
GLP-1 medications are not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN2 (Multiple Endocrine Neoplasia syndrome type 2), a history of pancreatitis, or anyone currently pregnant or breastfeeding
Thiazolidinediones (TZD) were expected to improve the asthma outcomes as they reduce insulin resistance by activating PPAR- pathways
-Six months of needle therapy, Roche/Alnylam's new SiRNA antihypertensive drug is planned to be included in breakthrough therapies On June 2, 2026, the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced that Roche's Zilebesiran is intended to be included as a breakthrough therapy for adult hypertensive patients with cardiovascular disease or high risk of cardiovascular disease, in order to reduce the risk of cardiovascular death, non fatal myocardial infarction, non fatal stroke, and heart failure events (hospitalization or emergency treatment for heart failure)
After enrolling, youll receive a Welcome Kit with the tools you need to start your journey
